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Abstract
Although relatively rare, polymorphous adenocarcinoma (PAC) is likely the second most common malignancy of the minor 
salivary glands (MiSG). The diagnosis is mainly based on an incisional biopsy. The optimal treatment comprises wide 
surgical excision, often with adjuvant radiotherapy. In general, PAC has a good prognosis. Previously, PAC was referred to 
as polymorphous low-grade adenocarcinoma (PLGA), but the new WHO classification of salivary gland tumours has also 
included under the PAC subheading, the so-called cribriform adenocarcinoma of minor salivary glands (CAMSG). This 
approach raised controversy, predominantly because of possible differences in clinical behaviour. For example, PLGA (PAC, 
classical variant) only rarely metastasizes, whereas CAMSG  often shows metastases to the neck lymph nodes. Given the 
controversy, this review reappraises the definition, epidemiology, clinical presentation, diagnostic work-up, genetics, treat-
ment modalities, and prognosis of PAC of the salivary glands with a particular focus on contrasting differences with CAMSG.
Keywords Polymorphous adenocarcinoma · Pathology · Salivary glands · Therapy · Prognosis · Polymorphous low-grade 
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Introduction
Polymorphous adenocarcinoma (PAC) of the minor salivary 
glands (MiSG) is a rare head and neck cancer, which gener-
ally has a good prognosis following adequate multidisci-
plinary treatment. Regarding this entity, recently, the his-
topathological landscape has been redesigned. Most PACs 
were previously known as “polymorphous low-grade adeno-
carcinoma” (PLGA), but the recent WHO classification of 
salivary gland tumours includes under the PAC heading, 
besides the classical PLGA, also the so-called “cribriform 
adenocarcinoma of minor salivary glands” (CAMSG). This 
approach has met controversy predominantly because of 
purported important differences in clinical behaviour. For 
example, PLGA (PAC, classical variant) only rarely metas-
tasizes, whereas CAMSG often shows regional metastases.
In view of the controversy, this review by the International 
Head and Neck Scientific Group (IHNSG) aims to critically 
reappraise the recent literature on PAC, and to integrate recent 
findings into the existing knowledge base, predicated on exten-
sive clinical experience. Comparable efforts have been already 
published for adenoid cystic carcinoma, mucoepidermoid car-
cinoma and acinic cell carcinoma [1–3]. The definition, epi-
demiology, clinical presentation, diagnostic work-up, genetics, 
treatment modalities, and prognosis of PAC are revisited, with 
a particular focus on contrasting differences between PLGA 
and CAMSG. In this manuscript, the term PAC refers to PLGA 
or “PAC, classical variant”, whenever studies containing data 
from before the latest WHO classification are referred to.
Methods
A literature search was conducted using PubMed and Sci-
enceDirect, based on the MeSH terms “polymorphous low-
grade adenocarcinoma”, “polymorphous low-grade papillary 
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adenoma”, “salivary lobular carcinoma”, “salivary terminal-
duct adenocarcinoma”, “polymorphous adenocarcinoma”, 
and “cribriform adenocarcinoma of the minor salivary 
gland”, spanning the period 1984–2017. Based on title and 
abstract, a total of 462 manuscripts were included in the final 
database that provided the basis for this review. An additional 
13 manuscripts were added through reference tracking.
Historical survey and definition
Freedman and Lumerman should be credited with the first 
clinicopathological description of what is now referred to 
as “polymorphous adenocarcinoma” (PAC) in 1983, though 
they suggested the term “lobular carcinoma” to empha-
size similarities with the single-file (‘Indian-file’) cellular 
infiltrates seen in breast lobular carcinoma [4]. The same 
year Batsakis et al. reported a series of similar tumours as 
“terminal-duct adenocarcinoma” to reflect their purported 
origin from the intercalated (terminal/distal) segment of 
salivary ducts [5]. Previously, it is likely that PAC had been 
diagnosed as non-specific adenocarcinoma or adenoid cystic 
carcinoma (AdCC). In 1984, however, Evans and Batsakis 
suggested the term “polymorphous low-grade adenocarci-
noma” (PLGA) for this group of largely MiSG tumours that 
were characterized by blunt/uniform cytology, but histologi-
cally diverse architectural patterns (see “Microscopic fea-
tures” below) [6]. The latter varied both within and among 
the individual tumours [6]. The term PLGA enjoyed wide-
spread endorsement and in 1991 the World Health Organi-
zation (WHO), in its 2nd classification of histological 
typing of salivary gland tumours, adopted it to emphasize 
the polymorphous histology and rather indolent clinical 
behaviour [7]. Between the original reports and the 1991 
WHO publication, approximately 130 cases of PLGA were 
reported in the English literature [8]. The interest in PLGA 
gained momentum and culminated with the publication in 
1996 of the Armed Forces Institute of Pathology volume 
on tumours of the salivary glands by Ellis and Auclair [9]. 
This text provided a good review of the literature together 
with a detailed pathological description, illustrations, and 
differential diagnosis, and became the standard reference.
Increasing clinical experience eventually indicated that 
PLGA is not always as indolent as initially thought [10]. In 
addition and similarly to other salivary carcinomas (e.g., 
AdCC [11], acinic cell carcinoma [12]), high-grade trans-
formation of PLGA was described [13]. Differences in his-
topathological interpretation and factors such as pT and 
site apart, it was on those grounds, that in 2017, the WHO 
opted for the term PAC and defined it as “a malignant epi-
thelial tumour characterized by cytological uniformity, 
morphological diversity, and an infiltrative growth pattern” 
[14–16]. The value of this decision remains to be seen.
In 1999, a type of adenocarcinoma occurring in the 
posterior lateral/base of tongue and frequently showing 
synchronous metastases in cervical lymph nodes, was 
described [17]. It was named “cribriform adenocarci-
noma of the tongue” (CAT) and, given some histological 
resemblance to papillary thyroid carcinoma (PTC), was 
hypothesized to arise from the thyroglossal duct anlage 
[17]. This concept, however, was not universally accepted, 
arguments against being that the thyroglossal duct is not 
lateral, the site possibly influenced the rate of metastases, 
and that CAT shared histological features with conven-
tional PLGA. Accordingly, the 2005 WHO publication 
classified CAT as a subtype of PLGA [18]. Interestingly, 
CAT was later reported in MiSGs other than the ones 
located in the tongue (see “Clinical features” below), and 
was thus renamed “cribriform adenocarcinoma of minor 
salivary gland origin” (CAMSG) [19]. Despite the pur-
ported similarity of CAMSG cells to PTC, the differences 
in site distribution, the higher regional aggressiveness, and 
partly different genetic alterations found in PLGA (PAC, 
classical variant) and CAMSG (see “Genetic analysis” 
below), the 2017 WHO classification decided to retain 
CAMSG under the PAC subheading [15, 20]. This is sup-
ported by the histologic and immunophenotypic similari-
ties, the existence of tumours with histologic features of 
both PLGA (PAC, classical variant) and CAMSG, compa-
rable survival rates, absence of distant metastasis in both 
entities, and the observation that PLGA (PAC, classical 
variant) and CAMSG are driven by genes of the same fam-
ily (see “Genetic analysis” below). Debate on whether to 
separate CAMSG from PAC or not is still ongoing [20] 
and more research is desirable to make conclusive deci-
sions [16]. In view of the ongoing debate, CAMSG will 
be separately treated in this review.
Epidemiology
Obviously, available epidemiological studies date back to 
the time period before the recent definition of PAC, and 
mainly focus on PLGA (PAC, classical variant), and not on 
the rare entity of CAMSG. The recently reported increased 
proportion of these tumours [21–23] should be interpreted 
with caution, since this may reflect improved diagnostics. 
Salivary cancers account for 5.9% of the yearly incidence 
of head and neck cancers [24]. Approximately 0.44–2.47% 
of all benign and malignant salivary gland tumours are 
PLGAs [14, 21, 25, 26]. De Araujo et al. performed an 
extensive literature review of mainly institution-based 
series between 1992 and 2012, and found a varying fre-
quency of PLGAs among MiSG carcinomas, calculating 
an average proportion of 6.3% (431 cases out of a total of 
6891) [22]. This number is obviously subjected to both 
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referral and diagnostic biases within centres and among 
centres, and it is, therefore, better to focus on population-
based registries. Considering “all salivary gland malig-
nancies” in a population-based registry in the UK, PLGA 
constitutes about 11.5% [21]. Given the almost exclusive 
MiSG origin [27], the proportion of 41% of MiSG carci-
nomas is clinically the most meaningful one [21]. Thus, 
PLGA (PAC, classical variant) with or without CAMSG 
inclusive is the second most common intraoral salivary 
cancer after mucoepidermoid carcinoma. The recent analy-
sis of the United States National Cancer Institute’s Sur-
veillance, Epidemiology, and End Results (SEER) Data-
base on PLGA (2001–2011) provides the most accurate 
epidemiologic information and reports an annual incidence 
rate of 0.051 PLGA per 100,000 [28].
The tumour predominantly affects women, with an F:M 
ratio of around 2–1 [10, 28–32]. Over 90% of PLGAs 
occur above 40 years of age, with comparable incidence 
rates per decade from 40 to 79 years, and a mean age at 
diagnosis of 61.3 years [28]. The site is discussed below. 
Over 75% of PLGAs were diagnosed in whites, approxi-
mately 20% in coloured people, and less than 2% in Asians 
[28].
Regarding CAMSG, only around 50 cases have been 
described, which limits epidemiological conclusions. 
CAMSG affects males and females approximately equally 
and age at diagnosis ranges from 25 to 85 years (mean 
53 years) [20].
Clinical features
For consistency with the latest WHO classification, the 
term PAC will be used, but it is re-emphasized that data 
were collected in the era when the tumour was referred to 
as PLGA. PAC is mainly described in the posterior hard 
and soft palate (Fig. 1) [25, 28, 33]. Labial and buccal 
mucosa are also involved [10, 25, 28]. Up to 9% of PACs 
have been reported to originate from major salivary glands, 
with the parotid affected in more than half of these cases 
[21, 28], but in our collective experience; however, bona 
fide PACs of the major salivary glands are rare. Even less 
frequently, PAC of the nasal cavity and paranasal sinuses 
has been described [28, 34]. Cases of laryngeal, tracheal, 
bronchial, breast, intramandibular, intramaxillary, lacri-
mal, and synchronous bilateral oral presentation of PAC 
have been reported as well [35–42]. PAC-like tumours in 
other sites are outside the scope of this review.
CAMSG predominantly involves the base of the tongue, 
but has been described in the retromolar region, palate, 
upper lip and tonsils [19]. Recently, a case of CAMSG origi-
nating from the epiglottis has been reported [43].
Most patients with a PAC show a mass with a mean size 
at presentation of 2.1 cm (± SD 1.3 cm) (Fig. 1) [28]. PAC 
of the lip is likely smaller at first presentation, probably due 
to easier visualisation [10]. Conversely, CAMSG, being at 
a less visible site, typically is approximately 1 cm larger 
than PAC at presentation [19]. Only a minority presents 
with pain, ulceration, bleeding or ill-fitting dentures [44]. 
When experienced and on average, symptoms are present 
for over 2 years [10]. A possible presentation may be of 
stippled mucosa overlying the tumour, attributable to surface 
papillary epithelial hyperplasia [45]. Bone invasion may be 
occasionally seen in the hard palate and nasopharynx [46].
An apparent difference between PLGA (PAC, classical 
variant) and CAMSG is the pattern of metastasis: only 1 
in 10 PLGA (PAC, classical variant) patients presents with 
nodal metastasis [28, 29, 47], as opposed to 7 in 10 patients 
with CAMSG [19]. In the latter, nodal disease can even 
be the first symptom [48]. As already noted, the particular 
site may account for this and the rich lymphatic network 
therein may also be significant [46]. Approximately 4% of 
PLGAs (PAC, classical variant) have distant metastases at 
diagnosis [28], mainly in the lungs, but abdominal, orbital 
and skin metastases have also been described [49–53]. Only 
one CAMSG case with lung and bone metastases has been 
reported [54].
Pre‑operative assessment: imaging
Similar to other salivary malignancies, the imaging tech-
niques pre-operatively used for treatment planning are ultra-
sound (US), computed tomography (CT), magnetic reso-
nance imaging (MRI), and positron-emission tomography 
Fig. 1  PAC of the hard palate in a male aged 37 years. (Courtesy of 
Associate Professor Panagiota Economopoulou, University of Athens, 
Greece)
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combined with CT (PET-CT) [55]. PAC has non-specific 
imaging features [56], but the main goal is to assess the 
local extent including bone and cartilage involvement (espe-
cially when the tumour arises in the palate, sinuses, naso-
pharynx or larynx), and any regional lymph node involve-
ment (particularly for tumours at the base of tongue) rather 
than providing a specific diagnosis [33, 55, 57]. US can-
not differentiate PAC from most other carcinomas, as most 
show similar echotexture [58], but can be helpful in guid-
ing fine-needle aspiration (FNA) of suspicious lymph nodes 
[59]. MRI should be performed in all salivary tumours and 
typically, PAC has a low T1 signal intensity and a high- to 
iso-T2 intensity [34]. CT has proved to be better in assess-
ing bone erosion [33, 58] and shows PAC as an irregular, 
low-density lesion with irregular enhancement or bone 
involvement [40]. MRI suffers less from metallic artefacts 
(e.g., dental amalgam restorations) and is superior to CT 
for pre-operative assessment of tumour border, bone inva-
sion, nodal metastases [60, 61], and perineural spread. For 
the latter, the preferred sequence is the contrast-enhanced 
fat-suppressed T1-weighted image [56]. 18F-FDG-PET or 
PET/CT may also be useful to stage and restage PAC, but 
given the low rate of M+ disease, its added value compared 
to conventional imaging is questionable [55]. A chest X-ray 
or, preferably, a low-dose chest CT, is recommended for 
pre-operative staging of lung metastases [49–51, 62].
Pre‑operative assessment: biopsy 
and cytology
Pre-operative tissue diagnosis for PAC of the oral cavity and 
oropharynx, primarily relies on an incisional biopsy includ-
ing a margin of normal tissue [63–65]. The biopsy should be 
of adequate surface diameter and depth to allow a confident 
diagnosis; small sized incisional or punch-type biopsies may 
result in a differential diagnosis only and diagnostic difficul-
ties because of the diverse cyto-architectural patterns.
For evaluation of major salivary gland lesions and sus-
picious neck nodes, FNA cytology (FNAC) and, less fre-
quently, core needle biopsy (CNB) are used [66]. In cell-rich 
smears, irregular sheets and clusters of branching papillae 
may be seen. The nuclei are round to oval with scattered 
chromatin, inconspicuous nucleoli, whereas the cytoplasm 
is eosinophilic, dense, and moderate in amount [67, 68]. The 
matrix is myxohyaline [67, 68], often with bare nuclei in the 
background [67]. Aspirates show super-imposed nuclei with 
an irregular shape, punctate nucleoli and fine granular chro-
matin [69, 70]. The differential diagnoses include AdCC, 
pleomorphic adenoma (PA), and monomorphic adenoma 
(MA) [67, 71], and difficulties similar to the afore-men-
tioned for small sized incisional or punch-type biopsies are 
common. The presence of hyaline globules surrounded by 
tumour cells should probably tip the scales towards AdCC, 
but the results for diagnosing PAC by FNAC seem poor, with 
one study finding a specificity of 14% (1 out of 7) for palatal 
tumours [71]. Cytologic samples of CAMSG share some 
features (e.g., super-imposed nuclei) with PTC; this may 
be puzzling in a patient presenting with a neck node metas-
tasis from an unknown primary tumour [69, 70], though 
thyroglobulin immunohistochemistry can be performed on 
samples and may resolve the issue.
Despite the rather poor performance of FNAC, it should 
be emphasized that its main goal is distinguishing benign 
from malignant tumours, with a reported specificity of more 
than 90% in salivary glands in general [72]. A balanced 
approach on the value of FNAC and CNB in pre-operatively 
assessing salivary neoplasia is given by Howlett and Trian-
tafyllou [73].
Pathology
Macroscopic features
PAC, classical variant, typically is firm to solid, with an 
ovoid, unencapsulated, though grossly circumscribed, con-
tour. The tumour often lies in close proximity to the overly-
ing surface epithelium [10]. The cut surface is white or tan 
[74], whereas central tumour necrosis and haemorrhage are 
Fig. 2  a PAC of the lip. Histological section scanned to allow appre-
ciation of the ‘low-grade’, somewhat lobulated and deceptively ‘push-
ing’, though asymmetrical silhouette of the tumour (T). (E), labial 
epithelium; Gls, labial salivary glands M, orbicularis oris; Sk, skin. 
(Unless otherwise specified, the photomicrographs are from sections 
stained with haematoxylin and eosin.) b, c Deep portion of PACs of 
minor salivary glands. The invasive qualities of the tumour (T) can 
be appreciated. A satellite tumour nodule (arrow) and penetration of 
the superficial submucosal fat (F) are seen. The arrowhead indicates 
nerve bundles subadjacent to the tumour. d Superficial portion of 
PAC (T) of A minor salivary gland. The characteristic involvement of 
the lamina propria is seen. (E), oral epithelium. e PAC involves pre-
existing salivary mucous acini (straight arrows) and ducts (zigging 
arrow). The increased eosinophilia of the ducts allows distinction 
from the tumour parenchyma. f, g Cytological detail. H. The arrow 
indicates a mitotic figure. i, j Luminal ‘apocrine’ and non-luminal 
spindled phenotypes. The spindled cell (arrow) seems in the process 
of fraying-off into myxoid stroma (asterisk). Various architectural 
arrangements of the tumour cells. Largely solid islets in myxoid 
stroma (asterisk) (k); solid cords in fibrous stroma (asterisk) (l); lumi-
nal structures (m); pseudo-cribriform arrangements (n); single-file 
(‘Indian file’) arrangements (p); targetoid infiltration around a nerve 
(q). The non-rigid, collapsed and/or irregular silhouette of tumour 
lumina is appreciated in m and n. r ‘Pink’, eosinophilic annuli and 
bands of newly formed elastin (‘elastosis’) are present in the tumour 
stroma. s Canalicular adenoma (arrow) adjacent to a PAC (T) of the 
lip. t Nodal metastasis in CAMSG. u–w Primary CAMSG. While 
pseudo-cribriform appearance is dominant in u, v, solid patterns are 
seen in w. Note similarities to PTC nuclei in w; these are also appre-
ciated in t 
▸
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rare [10, 75, 76]. CAMSG is rubbery in consistency and 
white to gray in cut surface [17, 19, 20].
Microscopic features
The macroscopically described contour is reflected on 
whole mount preparations of PAC (Fig. 2a) and accords 
with a low-grade behaviour, but satellite nodules can be 
seen (Fig. 2b). The tumour invades adjacent salivary lob-
ules/fat (Fig. 2c) and is characteristically flooding the 
overlying lamina propria to reach the surface epithelium 
(Fig. 2d); the latter is in contrast to intraoral metastatic 
adenocarcinomas that are often submucosal [77]. Another 
common and characteristic feature is the continuation of 
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tumour to pre-existing parenchyma (Fig. 2e) [9]. It is 
not known whether this phenomenon reflects secondary 
spreading into or de novo origin from normal glandular 
parenchyma.
In PAC, the tumour cells per se show a uniform appear-
ance: shaped round or polygonal and small to medium sized 
with indistinct boundaries, slightly increased nuclear: cyto-
plasmic ratio, round or oval vesicular nuclei showing dis-
persed chromatin and inconspicuous nucleoli, and usually 
Fig. 2  (continued)
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eosinophilic cytoplasm (Fig. 2f, g). The nuclear and cyto-
plasmic features result in an overall ‘pale’ appearance of the 
tumour parenchyma, which was considered a useful diag-
nostic criterion in the past. Nuclear atypia or mitoses are 
not common (Fig. 2h) [6, 10, 29, 76, 78]; which had been 
overemphasized. Apocrine and spindled cell phenotypes 
can be seen (Fig. 2i, j), whereas oncocytes are exceedingly 
rare [79]. The spindled phenotypes may reflect attempts at 
myoepithelial differentiation and/or epithelial–mesenchymal 
transition.
As previously noted, PAC may show various cyto-
architectural patterns within a single tumour and between 
different tumours. The patterns vary in ratio, and include 
solid islands and cords, tubules, pseudo-cribriform aggre-
gates, and “Indian-file” infiltrates (Fig. 2k–p). The pseudo-
cribriform arrangements in PAC should be distinguished 
from the classic cribriform pattern of AdCC; they reflect 
true lumina, whereas the pattern in AdCC results from 
stromal cores trapped within the tumour parenchyma 
and thus outlined by basement membrane [80]. Papil-
lary arrangements are less common and never dominant. 
Finally, a targetoid pattern, concentrically around a small 
nerve bundle is not rare (Fig. 2q); this neurotropism has 
often been highlighted. Perivascular arrangements can also 
be seen [10, 13, 46, 47, 81].
PAC is set in variously myxoid fibrous/hyalinised or elas-
totic stroma with inconspicuous inflammation (Fig. 2k, l, r) 
[6, 10, 75]. Tyrosine-rich crystalloids and microcalcifica-
tions can be observed [79]. PAC-like components are not 
unusual in the context of carcinoma ex PA, whereas cana-
licular adenomas can be seen adjacent to PAC of the lip 
(Fig. 2s).
Fig. 2  (continued)
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Features of CAMSG are illustrated in Fig. 2t–w. The 
tumour cells often show pale and vesicular nuclei with 
ground-glass appearance which often overlap  and thus 
resemble the Orphan Annie Eye-nuclei of PTC (Fig. 2w). 
This may be a pitfall especially when such cells are found in 
a lymph node metastasis, when the primary tumour is 
unknown (Fig. 2t). Again, immunohistochemistry for thy-
roglobulin should be used when in doubt. The cytoplasm 
is often abundant and clear to eosinophilic. As in PAC, cel-
lular atypia and mitotic figures are rare [19, 82, 83]. The 
architecture of CAMSG is, however, considered different. 
A dominance of a pseudo-cribriform pattern may point 
towards CAMSG. Furthermore, CAMSG may be divided 
into cellular, solid or microcystic lobules by fibrous septa. 
Solid cellular aggregates often show a chromatically accen-
tuated  peripheral layer, consisting of palisaded tumour 
cells arranged perpendicular to the contour of the aggre-
gate. These peripheral areas are frequently detached from 
the rest of the tumour mass, which may render the tumour 
a papillary or glomeruloid appearance (Fig. 2u, v). The 
microcystic aggregates may have an alternating cribriform 
or tubular architecture, with the latter displaying monolay-
ered, secretion containing, similarly sized, luminal structures 
[10, 17, 48, 84]. CAMSGs often invade the muscular tis-
sue of the tongue and/or adjacent tissues and display lym-
phatic and occasionally also vascular invasion [19, 20, 69]. 
CAMSG is also set in hyalinized fibrous stroma with areas of 
myxoid matrix [17, 43, 69]. The features of nodal metastases 
resemble those of the primary (Fig. 2t).
The latest WHO recommendations, however, still ques-
tion the validity of these observations [15].
Immunohistochemistry
Concerning cytoskeleton and cytoplasmic filaments, PAC 
cells stain for vimentin and CK 7. CKs 8 and 18 are found in 
most solid nests, though only focally in predominantly pap-
illary tumours, where CK 14 is more frequently expressed. 
CKs 10, 13, and 19 are not expressed [85, 86].
Integrins β1, β2, and β3 can be detected in the pseudo-
cribriform areas [87]. The growth factors FGF-2, PDGF-
A, and PDGF-B and the receptors FGFR1, PDGFRA, and 
EGFR are more highly expressed in PAC than in normal 
salivary parenchyma [88].
Regarding cell cycle proteins, the anti-apoptotic mark-
ers BCL2 and survivin are strongly positive in PAC, while 
expression of the pro-apoptotic protein Bax is variable. The 
autophagy markers Beclin and LC3B, the most used marker 
of autophagosomes, are variably positive. The senescence 
markers p21 and p16 are predominantly negative or weakly 
positive. Taken together, these findings suggest that in PAC, 
autophagy, as a mechanism of cell survival under nutri-
ent depletion and hypoxia, plays a role to support tumour 
growth, further sustained by anti-apoptotic and anti-senes-
cence signals [89]. The Ki67 (MIB-1) proliferation index is 
usually less than 5% [90, 91].
S-100 protein is expressed in almost all PACs, the immu-
noreactivity being diffuse and strong (Fig. 3) [75, 76]. Up to 
80% of the cells may stain for WT1 [92]. In contrast, expres-
sion of smooth muscle actin (SMA) is inconsistent [93, 94]. 
A p63 positivity and absence of p40 immunostaining have 
also been reported [95].
The expression of mammaglobin and DOG-1 in PAC has 
been regarded as consistent with an origin from the inter-
calated (terminal/distal) segment of salivary ducts [5, 96].
As in PAC, CAMSG is strongly positive to CK7, CK8, 
CK18, S-100 protein, and vimentin. Furthermore, AE1-3, 
SOX10, and CAM5.2 are strongly expressed in CAMSG. 
A significant KIT expression is seen in almost half of the 
cases. Basal and myoepithelial markers such as p63, cal-
ponin, CK14, SMA, and CK5/6 are variably positive in all 
CAMSG, preferentially in the peripheral palisaded cells. 
Like PAC, CAMSG is also consistently p40 negative [97]. 
In contrast to PAC, CK19 stains in most CAMSG, though in 
a mild-to-moderate way. Immunostaining of p16 in CAMSG 
typically exhibits a patchy pattern, staining both cytoplasm 
and nuclei with variable portions of positive cells [19, 83, 
98].
Electron microscopy
This has been summarized by Dardick [80]. He notes vari-
ous proportions of luminal and non-luminal cells between 
regions of the same tumour and between individual cases. 
The non-luminal cells may express features of basal or 
myoepithelial cells, but their proportional volumes have not 
been calculated. In spite of this and the results of myofila-
ment immunohistochemistry (see above), the ultrastructural 
Fig. 3  Expression of S-100 protein in PAC
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findings have been interpreted as indicative of a biphasic 
structural organization, for PAC, similar to other epithe-
lial salivary tumours and the distal (acinar and intercalated 
ductal) segment of normal glandular parenchyma.
Genetic analysis
More than 70% of PAC exhibit activating mutations in the 
PRKD1 gene, that is a single-nucleotide variant (E710D), 
which affects a highly conserved amino acid in the catalytic 
loop of the kinase domain. The mutation increases both the 
kinase activity and cell proliferation and is likely to act as a 
driver of PAC [31]. One case with a PRKD2 rearrangement 
has also been described [99]. Thus, PRKD1 mutations define 
a large subset of PAC and may be used to distinguish it from 
its mimics.
In contrast to PAC, 80% of CAMSGs show rearrange-
ments rather that mutations in PRKD genes (PRKD1-3). 
The rearrangements result in recurrent ARID1A-PRKD1 and 
DDX3X-PRKD1 gene fusions, but the exact molecular con-
sequences remain to be determined. Cases with mixed PAC 
and CAMSG features may show either types of molecular 
alterations [98–101].
Differential diagnosis
This has been addressed by Ellis and Auclair [9] and Dard-
ick [80] on a variously histological basis. Guidance on dis-
tinguishing between PAC and AdCC, based on contour of 
tumour-cell aggregates, nature/contour of luminal spaces, 
and cytology, has also been tabulated [77]. Of the immu-
nohistochemical markers S-100 protein, WT1 and SMA 
are very helpful in distinguishing PAC from its mimics (see 
above). For example, S-100 protein and WT1 are regularly 
expressed in PAC, as opposed to AdCC, where staining for 
SMA is, however, more consistent [92–94]. These mark-
ers seem preferable over cKIT, p63 and p40 to distinguish 
between the two tumours. In addition, MYB overexpression 
is a hallmark of AdCC [101–103], but absent in PAC [104], 
which is rather identified by PRKD gene family alterations 
[31, 95, 100, 105, 106]. As regards distinction from PA, par-
ticularly when faced with small sized incisional and punch 
biopsies, CNBs and FNAC, a negative GFAP-staining would 
favour PAC [107]. PA also shows concordant p63 and p40 
expression (either both positive for both negative), whereas 
PAC is consistently p63 positive and p40 negative [95]. 
However, p40 does not feature in the immunohistochemical 
panel of every pathology laboratory.
There are no immunohistochemical markers distinguish-
ing PAC from CAMSG, adding to the ongoing discussion 
whether CAMSG should be regarded as a variant of PAC 
with dominant pseudo-cribriform component, or as a sepa-
rate entity. In metastatic lesions, CAMSG may be confused 
with PTC: the thyroid follicular markers thyroglobulin 
(see above) and TTF-1 are positive in PTC, but negative in 
CAMSG [19, 83].
High‑grade transformation
High-grade transformation in PAC is rare, but has been 
reported, especially in recurrent tumours, where radiother-
apy may be a causative factor. It is characterized by a pre-
dominantly solid growth pattern, nuclear atypia, prominent 
nucleoli, a high mitotic count, necrosis and frequent central 
haemorrhage [13, 108, 109]. To date, no cases of high-grade 
transformation have been described in CAMSG.
Management
Surgery
Primary wide surgical excision provides the best locore-
gional control for PAC (classical variant) and CAMSG 
[28, 34, 64, 65]. Even with a radical approach, one in three 
patients will have positive resection margins, possibly linked 
to the neurotropism that results in a tumour that escapes out 
of the surgical field, similar to what is observed in AdCC 
[64]. On the other hand, the local recurrences in the Mayo 
Clinic series all occurred despite negative surgical margins 
[44]. Prevention of recurrence is particularly important in 
PAC, since recurrent PAC may behave more aggressively 
[29]. Surgical excision is also the mainstay to treat recurrent 
tumours [10].
Palatal PAC with bone invasion often requires variably 
extended maxillectomy [63] combined with an obturator or 
an anatomical reconstruction to restore functionality [110]. 
Reconstruction can either be done immediately after the 
resection or delayed, following a disease-free time interval 
[63]. Different flaps and bone grafts have been proposed 
including myofascial temporalis flaps [111, 112], rotational 
flaps, vascularized fibular free flaps, iliac crest, and scapular 
osteocutaneous free flaps [63, 111]. Use of an obturator, 
when possible, has the advantages of potentially allowing 
an early detection of recurrence and a lower postoperative 
complication rate [63]. This should be weighed against the 
better functionality associated with free-flap reconstruction 
[113]. To achieve complete excision of CAMSG at the base 
of the tongue, transoral laser microscopic or robotic surgery 
may be preferred for smaller lesions, since it avoids the use 
of a mandibulotomy or suprahyoid release [65, 114, 115].
Since metastases to the neck lymph nodes are rare in 
PAC, neck dissection should generally be performed only in 
case of positive lymph nodes, observed clinically and/or on 
imaging [44, 76]. For PAC at the base of the tongue [46] and 
CAMSG [116], bilateral elective selective neck dissection 
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of levels II–III–IV can be considered, given the propensity 
for cervical nodal metastases [117].
Radiotherapy (RT)
RT is most often used postoperatively [28], in patients with 
extensive primary tumours or when section margins are not 
clear, when there is perivascular or perineural spread ahead 
of the main front in the resected specimen [118], and/or when 
cervical nodal metastases are found [63, 119]. Radiotherapy 
is used both in PAC and CAMSG. Currently, intensity-mod-
ulated radiotherapy (IMRT) is the standard, usually with a 
total dose to a tumour bed of 60 Gy (in completely excised 
tumours/R0 resection) or 66 Gy (when there is a microscopi-
cally involved/R1 resection) [65, 120]. Further improvement 
in terms of toxicity and dosimetric profile over conventional 
photon beam radiotherapy can be expected with the use of 
protons as monotherapy in patients with their tumour close to 
critical structures such as the orbital apex, those unfit for sur-
gery or those with an unresectable tumour [65, 121]. IMRT 
has been proposed as a useful adjuvant therapy in parotid 
PAC when being conservative towards the facial nerve and/
or in advanced-stage primary tumours [122, 123]. For MiSG 
tumours in general, radiotherapy has also been recommended 
as adjuvant therapy in tumours with advanced T and/or N 
status, when bone or muscle invasion is found, or when the 
tumour has a paranasal sinusal localization [65, 124, 125]. 
Thus far, type-specific data supporting the use of adjuvant 
radiotherapy in PAC or CAMSG are lacking.
Chemotherapy
In general, the use of chemotherapy in malignant MiSG 
tumours is restricted to palliative cases [65]. It may be used 
concomitantly with radiotherapy for unresectable MiSG 
tumours, when the patient refuses surgery or is inoperable, 
or in the postoperative setting [10, 65, 126, 127]. No type-
specific evidence supporting the use of chemotherapy in 
PAC or CAMSG is currently available [10, 47].
Follow‑up
Patients treated for PAC should have regular assessments 
for any recurrence [44, 63, 128]. Initially, the follow-up is 
not different from other head and neck malignancies [62], 
but a minimum of 15–20 years has been suggested, since 
recurrence may well occur after 5 years [44, 111]. Clinical 
examination and MRI are the recommended tools for locore-
gional monitoring [129]. Use of 18F-FDG-PET or PET/CT 
has also been proposed for post-surgical follow-up, but this 
may not be cost effective [55]. Chest X-ray or low-dose chest 
CT should be performed periodically, to detect pulmonary 
metastases early [49, 62].
Local recurrence has been described in CAMSG, as well 
as delayed cervical lymph node metastasis, necessitating a 
comparable follow-up scheme [19, 84, 130].
Prognosis
In general, patients affected by PAC have a good prognosis. 
This accords with the low Ki67 index of PACs (see above), 
which is suggestive of slow growth. The SEER database 
analysis showed a 5- and 10-year disease-specific survival 
(DSS) of 98.6 and 96.4%, respectively [28]. However, PAC 
should not be complacently regarded as a uniformly low-
grade tumour, since it may recur, metastasize and even 
cause death [54]—hence, the decision of the WHO to 
rename PLGA into PAC [15]. Local recurrence of PAC has 
been reported to be 5.3–33% over a 5–10 year period [10, 
16, 28, 46], the average time interval being approximately 
70 months. Nevertheless, recurrences have been described 
even 24 years after primary tumour removal [64].
Table 1 summarizes statistically corroborated adverse 
prognosticators for PAC in a statistically significant way, 
mainly assessed by univariate analysis. These include site, 
angiolymphatic-, perineural- or bone invasion, necrosis, size, 
UICC stage, papillary and pseudo-cribriform components, 
positive resection margins and the use of radiotherapy with-
out surgery [28, 32, 46, 54]. Probably, the latter is influenced 
by a negative selection bias; radiotherapy without surgery is 
usually reserved for patients not fit for surgery or those with 
advanced-stage disease [28].
CAMSG has also a good prognosis [17, 84]. Local recur-
rence rates of 10–30% have been reported, while cervical 
lymph node metastasis may occur years after excision of the 
primary tumour [19, 20]. So far, one death due to CAMSG 
has been reported [54].
Epilogue
PAC seems the second most common MiSG cancer. Large 
population-based studies confirm its usually good prog-
nosis. Nevertheless, the occurrence of regional metastasis 
in especially the CAMSG spectrum of the disease, as well 
as the possible high-grade transformation in PAC underlie 
the recent decision of the WHO to remove the “low-grade” 
indication from the term. Further research should focus on 
improving the treatment, while more evidence is necessary 
to make a conclusive decision whether to regard CAMSG 
as a separate entity or part of the PAC spectrum. These two 
entities remain grouped under one umbrella in the latest edi-
tion of the WHO classification, but further investigations 
are desirable and may provide different options for future 
targeted therapy.
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